ONCOLOGY THE REAL THERAPY FOR A BETTER TOMORROW
Oncology is rapidly shifting from one-size-fits-all treatment toward biomarker-led, targeted and individualized therapies. The material highlights four major clinical trends: targeted combinations, earlier use of antibody-drug conjugates (ADCs), more precise immunotherapy, and the continued expansion of cell therapies such as CAR-T. The global need remains enormous, with the material citing ~20 million new cancer cases, 9.74 million cancer deaths and 53.5 million people living within five years of diagnosis based on GLOBOCAN 2022. This creates a strategic imperative to connect science, data and patient access so that clinical innovation translates into measurable patient benefit. The competitive landscape is also evolving beyond traditional Big Pharma. The report identifies 20 mid-size/specialist biotech companies working across CAR-T, ADCs, bispecific antibodies, RAS inhibitors, precision oncology, targeted degraders and other emerging platforms. Looking beyond 2025, five strategic shifts stand out: Science, Precision, Data, Access and Collaboration. Biomarker-led enrollment, molecular profiling, real-world evidence, ctDNA, integrated clinical data, better diagnostics/manufacturing and collaboration between biotech, pharma, academia and health systems are expected to shape the next phase of oncology innovation. Bottom line: The future of oncology is not simply about extending survival—it is about using precision science, data and collaboration to deliver the right therapy to the right patient while improving quality and possibility of life.
THE REAL THERAPY FOR A BETTER TOMORROW
Medifirm Intelledge Global Private Limited
Healthcare Solutions | Intelligence | Impact
Selected clinical-trial signals visible by December 2025
01 — TARGETED + IMMUNOTHERAPY
INAVO120: Inavolisib + palbociclib/fulvestrant produced median OS of 34.0 vs 27.0 months, with HR 0.67, in PIK3CA-mutated, HR+/HER2− advanced breast cancer.
Key signal: 34.0 vs 27.0 months OS
02 — ADCS MOVE EARLIER
DESTINY-Breast09: Trastuzumab deruxtecan + pertuzumab achieved median PFS of 40.7 vs 26.9 months, with HR 0.56, in first-line HER2+ metastatic breast cancer.
Key signal: 44% lower progression/death risk
03 — IMMUNOTHERAPY BECOMES MORE PRECISE
A Phase III dMMR colon-cancer study reported a 50% reduction in recurrence/death with FOLFOX + atezolizumab versus chemotherapy alone in stage III disease.
Key signal: 50% risk reduction
04 — CELL THERAPY EXPANDS
CAR-T and other cellular therapies continued moving beyond classic hematologic indications, while biomarker selection and manufacturing readiness remained critical execution layers.
Key signal: Platform + manufacturing matter
Overall Oncology Shift
Oncology is shifting from one-size-fits-all treatment toward biomarker-led combinations, targeted delivery and individualized immune/cell therapy.
Sources: ASCO 2025; Journal of Clinical Oncology 2025; NEJM 2025; ESMO 2025; FDA oncology approvals; ClinicalTrials.gov. Selected examples, not an exhaustive trial review.
Data cutoff: 31 December 2025
02 — WHY ONCOLOGY INNOVATION IS A GLOBAL PATIENT SUPPORT SYSTEM
Latest global burden available by 31 Dec 2025: GLOBOCAN 2022
Global Cancer Burden
20.0M
New cancer cases worldwide
9.74M
Cancer deaths worldwide
53.5M
People living within 5 years of diagnosis
1 IN 5
People develop cancer in their lifetime
Source: GLOBOCAN 2022
1 — HIGH UNMET NEED
Cancer remains a leading global cause of death; the burden is projected to rise sharply with population growth and ageing.
2 — BETTER SURVIVAL
The objective is no longer simply tumor shrinkage; durable control, overall survival and quality of life increasingly shape development.
3 — PRECISION CARE
Biomarkers such as HER2, PIK3CA, dMMR and actionable oncogenic drivers are turning population treatment into patient segmentation.
4 — ACCESS + EQUITY
A breakthrough only becomes meaningful when diagnosis, companion diagnostics, treatment delivery and affordability reach patients.
5 — DATA-DRIVEN DEVELOPMENT
Real-world evidence, molecular profiling, ctDNA and smarter trial design can reduce uncertainty and improve patient selection.
Strategic Opportunity
The strategic opportunity: connect science + data + access so that clinical innovation translates into measurable patient benefit.
Source: IARC/WHO GLOBOCAN 2022 — the latest global burden dataset available by the Dec 2025 cutoff. ~20.0M new cases, 9.74M deaths and 53.5M 5-year prevalent cases.
Data cutoff: 31 December 2025
03 — TOP 20 MID-SIZE / SPECIALIST BIOTECHS
CHALLENGING BIG PHARMA IN ONCOLOGY — DEC 2025
Selected for differentiated oncology platforms, clinical momentum or strategic relevance; “mid-size” is directional, not a strict market-cap threshold.
# Company Focus Why It Matters
1 BeOne Medicines Heme; solid tumors BTK/BCL-2 + global scale
2 Genmab Antibodies; bispecifics Differentiated antibody platforms
3 Revolution Medicines RAS(ON) inhibitors RAS-driven solid tumors
4 Summit Therapeutics PD-1/VEGF bispecific Ivonescimab / lung cancer
5 Legend Biotech CAR-T BCMA cell therapy
6 Iovance Biotherapeutics TIL therapy Personalized cellular therapy
7 Arcus Biosciences Immuno-oncology PD-1/TIGIT & combinations
8 Zymeworks Bispecifics; ADCs Multispecific antibody platform
9 Cullinan Therapeutics Targeted protein degraders Degrader-based oncology
10 Olema Oncology ER-targeted therapy Next-gen oral ER degraders
11 Immunocore TCR bispecifics ImmTAC platform
12 IDEAYA Biosciences Precision oncology Synthetic lethality / biomarker-led
13 Relay Therapeutics Small molecules Protein-motion drug discovery
14 Tango Therapeutics Immuno-oncology Genetically defined targets
15 Xencor Bispecific antibodies XmAb immune-cell engagers
16 Janux Therapeutics T-cell engagers Tumor-activated T-cell platform
17 Bicara Therapeutics Bispecific immunotherapy EGFR/TGF-β approach
18 Arcellx CAR-T Next-gen cell therapy platform
19 Kura Oncology Targeted oncology Menin inhibition / AML
20 Mersana Therapeutics ADCs Next-gen ADC platform
Why This Matters
Platform companies can create new mechanisms, validate novel targets and become partners or future competitors — to the largest pharma portfolios.
Company selection is a Medifirm editorial shortlist based on public company materials, pipeline focus and oncology relevance available by Dec 2025; not an investment ranking or recommendation.
Data cutoff: 31 December 2025
04 — THE FUTURE OF ONCOLOGY IS BRIGHT
TOGETHER, WE CAN OUTSMART CANCER
Five strategic shifts to watch after 2025
01 — SCIENCE
Novel targets, ADC payloads, bispecifics, RAS inhibition and cellular therapies.
02 — PRECISION
Biomarker-led enrollment, molecular profiling and adaptive treatment selection.
03 — DATA
Real-world evidence, ctDNA and integrated clinical data to improve decisions.
04 — ACCESS
Diagnostics, manufacturing, affordability and delivery must scale with innovation.
05 — COLLABORATION
Biotech + pharma + academia + health systems can compress development timelines.
THE BIGGER MESSAGE
ONCOLOGY IS NOT ONLY ABOUT EXTENDING LIFE — IT IS ABOUT IMPROVING THE QUALITY, AND POSSIBILITY OF LIFE.
LET'S CONNECT. COLLABORATE. CURE.
Medifirm Intelledge Global Private Limited
AI-powered intelligence for better decisions in healthcare & oncology
Website:
medifirmintelledgeglobal.com
Support:
support.medlii@medifirmintelledgeglobal.com
USA-based Head:
anthony@medifirmintelledgeglobal.com
India-based Head:
srishti.sonewal@medifirmintelledgeglobal.com
Disclaimer
General informational/educational purposes only. Not medical, clinical, regulatory, investment or treatment advice. Trial and company information reflects public sources through 31 Dec 2025 and may change. Verify primary sources before decisions.
Data cutoff: 31 December 2025